Dysregulation of the epigenome drives aberrant transcriptional programmes that promote
cancer onset and progression. Although defective gene regulation often affects oncogenic …

DNA hypomethylation was the initial epigenetic abnormality recognized in human tumors.
However, for several decades after its independent discovery by two laboratories in 1983, it …

Immunotherapy strategies targeting the programmed cell death ligand 1 (PD-
L1)/programmed cell death 1 (PD-1) pathway in clinical treatments have achieved …

Epigenetic therapies, including DNA methyltransferase and histone deacetylase inhibitors,
represent important new treatment modalities in hematologic malignancies, but their …

Like all other mammals, humans harbour an astonishing number of endogenous
retroviruses (ERVs), as well as other retroelements, embedded in their genome. These …

Downregulation/loss of the antigen presentation is a major immune escape mechanism in
cancer. It allows tumour cells to become 'invisible'and avoid immune attack by antitumour T …

Immune-mediated diseases are clinically heterogeneous but they share genetic and
pathogenic mechanisms. These diseases may develop from the interplay of genetic factors …

The lack of second-line treatment for relapsed ovarian cancer necessitates the development
of improved combination therapies. Targeted therapy and immunotherapy each confer …

Genomic instability and genetic mutations can lead to exhibition of several cancer hallmarks
in affected cells such as sustained proliferative signaling, evasion of growth suppression …

Immune checkpoint inhibitors (ICI) have significantly improved treatment outcomes for
several types of cancer over the past decade, but significant challenges that limit wider …